Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of SGLT2 inhibitor and DPP-4 inhibitor as add-on therapy in subjects with type 2 diabetes inadequately controlled on insulin plus metformin-based regimens
KCT0004959Phase 4Terminated
- Sponsor
- Daewoong Pharmaceutical
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of SGLT2 inhibitor + DPP-4 inhibitor in type 2 diabetes mellitus (T2DM), sponsored by Daewoong Pharmaceutical. Started May 2022; status: terminated.
02
Drugs
SGLT2 inhibitor + DPP-4 inhibitor
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0004959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004959.